EA200401470A1 - Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение - Google Patents

Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение

Info

Publication number
EA200401470A1
EA200401470A1 EA200401470A EA200401470A EA200401470A1 EA 200401470 A1 EA200401470 A1 EA 200401470A1 EA 200401470 A EA200401470 A EA 200401470A EA 200401470 A EA200401470 A EA 200401470A EA 200401470 A1 EA200401470 A1 EA 200401470A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
derivatives
atom
alkoxy
alkyl
Prior art date
Application number
EA200401470A
Other languages
English (en)
Other versions
EA007501B1 (ru
Inventor
Франсуаза Боно
Мишель Бош
Виктор Дос Сантос
Жан Марк Эрбер
Дино Нисато
Бернар Тоннерр
Жан Ваньон
Original Assignee
Санофи-Авентис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи-Авентис filed Critical Санофи-Авентис
Publication of EA200401470A1 publication Critical patent/EA200401470A1/ru
Publication of EA007501B1 publication Critical patent/EA007501B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Данное изобретение относится к производным 1-замещенного пиперазинилацилпиперидина общей формулы (I), где n равен 1 или 2; p равен 1 или 2; Rпредставляет собой атом галогена, радикал трифторметил, (C-C)алкил, (C-C)алкокси, радикал трифторметокси; Rпредставляет собой атом водорода или атом галогена; Rпредставляет собой атом водорода, группу -OR, группу -CHOR, группу -NRR; группу -NRCOR; группу -NRCONRR; группу -CHNRR; группу -CHNRCONRR; (C-C)алкоксикарбонил; группу -CONRR; или Rобразует двойную связь между атомом углерода, к которому он присоединен, и соседним атомом углерода пиперидинового цикла; Rпредставляет собой ароматическую группу, выбранную из (II), причем указанные ароматические группы являются незамещенными, монозамещенными или дизамещенными заместителем, независимо выбранным из атома галогена, (C-C)алкила, (C-C)алкокси, радикала трифторметил. Данное изобретение также относится к способу получения указанных соединений и их терапевтическому применению.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200401470A 2002-06-07 2003-06-05 Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение EA007501B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207001 2002-06-07
PCT/FR2003/001685 WO2003104225A1 (fr) 2002-06-07 2003-06-05 Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
EA200401470A1 true EA200401470A1 (ru) 2005-06-30
EA007501B1 EA007501B1 (ru) 2006-10-27

Family

ID=29724874

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401470A EA007501B1 (ru) 2002-06-07 2003-06-05 Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение

Country Status (30)

Country Link
US (2) US7294628B2 (ru)
EP (2) EP1513835B1 (ru)
JP (2) JP4441401B2 (ru)
KR (1) KR100970812B1 (ru)
CN (1) CN100448875C (ru)
AR (2) AR040247A1 (ru)
AT (2) ATE336491T1 (ru)
AU (2) AU2003255645A1 (ru)
BR (1) BR0311828A (ru)
CA (1) CA2487840C (ru)
CY (2) CY1107330T1 (ru)
DE (2) DE60307632T2 (ru)
DK (2) DK1513836T3 (ru)
EA (1) EA007501B1 (ru)
ES (2) ES2271637T3 (ru)
HK (1) HK1076110A1 (ru)
HR (1) HRP20041157B1 (ru)
IS (1) IS2302B (ru)
MA (1) MA27233A1 (ru)
ME (1) MEP11508A (ru)
MX (1) MXPA04012341A (ru)
NO (1) NO329669B1 (ru)
NZ (1) NZ537044A (ru)
PL (1) PL208711B1 (ru)
PT (2) PT1513835E (ru)
RS (2) RS20050014A (ru)
TW (2) TWI319400B (ru)
UA (1) UA77526C2 (ru)
WO (2) WO2003104225A1 (ru)
ZA (1) ZA200409823B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
EP1706392A2 (en) * 2004-01-08 2006-10-04 Syngenta Participations AG Pesticidal heterocyclic dihaloallyl compounds
KR20070036148A (ko) * 2004-07-16 2007-04-02 얀센 파마슈티카 엔.브이. 신경병성 질환의 치료에 적합한 피페리딘, 피페라진 혹은모르폴린의 이량체 화합물 또는 그들의 7-원 유사체
MX2007003318A (es) * 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
JP2008536844A (ja) * 2005-04-15 2008-09-11 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ニューロトロフィン類似体を用いた細胞生存促進法
US8232274B2 (en) * 2007-03-15 2012-07-31 Albany Molecular Research, Inc. Pyridazinone derivatives useful as glucan synthase inhibitors
RU2497819C2 (ru) * 2007-05-21 2013-11-10 Ривайва Фармасьютикалс, Инк. Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
CN108383804A (zh) 2009-11-12 2018-08-10 特罗菲克斯制药股份有限公司 神经营养蛋白模拟化合物及其盐的晶型
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
AU2010333338A1 (en) 2009-12-14 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
AU2018334290A1 (en) * 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
TWI828758B (zh) 2018-09-18 2024-01-11 美商金翅雀生技公司 噠嗪酮及其使用方法
EP3858439A1 (en) * 2020-02-03 2021-08-04 Esteve Pharmaceuticals, S.A. Amide derivatives having multimodal activity against pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208690B (en) * 1987-10-26 1993-12-28 Pfizer Process for producing 1-hjeterocyclic sulfonyl-3-(pyrimidinyl piperazinyl)-propane derivatives and pharmaceutical compositions comprising same
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
DE60307632D1 (de) 2006-09-28
MA27233A1 (fr) 2005-02-01
WO2003104226A1 (fr) 2003-12-18
CN1675203A (zh) 2005-09-28
MXPA04012341A (es) 2005-09-30
AR040246A1 (es) 2005-03-23
JP2005534661A (ja) 2005-11-17
DK1513836T3 (da) 2006-09-11
DK1513835T3 (da) 2006-12-27
NO20045331L (no) 2005-03-07
US20050176722A1 (en) 2005-08-11
EP1513835A1 (fr) 2005-03-16
PT1513836E (pt) 2006-09-29
IS7579A (is) 2004-12-02
NO329669B1 (no) 2010-11-29
BR0311828A (pt) 2005-03-29
US7294628B2 (en) 2007-11-13
PT1513835E (pt) 2006-12-29
US7468368B2 (en) 2008-12-23
ES2271637T3 (es) 2007-04-16
AU2003255644B2 (en) 2009-02-05
AU2003255645A1 (en) 2003-12-22
EA007501B1 (ru) 2006-10-27
JP4437075B2 (ja) 2010-03-24
CY1107330T1 (el) 2012-11-21
AU2003255644A1 (en) 2003-12-22
HRP20041157A2 (en) 2005-06-30
JP4441401B2 (ja) 2010-03-31
ES2264001T3 (es) 2006-12-16
NZ537044A (en) 2006-08-31
AR040247A1 (es) 2005-03-23
PL208711B1 (pl) 2011-05-31
KR100970812B1 (ko) 2010-07-16
RS52588B (en) 2013-04-30
EP1513836B1 (fr) 2006-05-03
CN100448875C (zh) 2009-01-07
HK1076110A1 (en) 2006-01-06
EP1513835B1 (fr) 2006-08-16
EP1513836A1 (fr) 2005-03-16
PL374729A1 (en) 2005-10-31
CA2487840A1 (en) 2003-12-18
ZA200409823B (en) 2006-07-26
MEP11508A (en) 2010-06-10
ATE325122T1 (de) 2006-06-15
TW200400185A (en) 2004-01-01
CA2487840C (en) 2011-05-17
KR20050008802A (ko) 2005-01-21
CY1105784T1 (el) 2011-02-02
WO2003104225A1 (fr) 2003-12-18
DE60305037T2 (de) 2006-12-14
JP2005533051A (ja) 2005-11-04
IS2302B (is) 2007-10-15
HRP20041157B1 (en) 2012-11-30
TW200407321A (en) 2004-05-16
RS20050014A (en) 2007-06-04
DE60307632T2 (de) 2007-08-09
UA77526C2 (en) 2006-12-15
DE60305037D1 (de) 2006-06-08
US20060167007A1 (en) 2006-07-27
TWI283671B (en) 2007-07-11
ATE336491T1 (de) 2006-09-15
TWI319400B (en) 2010-01-11

Similar Documents

Publication Publication Date Title
EA200401470A1 (ru) Производные пиперазинилацилпиперидина, их получение и их терапевтическое применение
DE60230266D1 (de) Phenylpyridincarbonyl piperazinderivate
LU92113I2 (fr) Perampanel et ses dérivés pharmaceutiquement acceptables (FYCOMPA)
DK1740584T3 (da) Kondenseret chinolinderivat og anvendelse deraf
EA200401282A1 (ru) Пиридиноилпиперидины как агонисты 5-ht1f
EA200701779A1 (ru) Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EA200870117A1 (ru) Азаиндоловые ингибиторы аурора-киназ
DE602004024093D1 (de) 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe
DK1063228T3 (da) Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf
HRP20090159T1 (en) Use of glucosidase inhibitors for therapy of mucovisidosis
TW200510440A (en) Novel compounds
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
TW200510377A (en) Novel compound having 4-pyridylalkylthio group as substituent
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
EA200801123A1 (ru) Производные 6-гетероарилпиридоиндолона, способ их получения и применение их в терапии
CO5660258A2 (es) Derivados de imidazol iii
PL1692098T3 (pl) Pochodna alfa-ketomidu oraz sposób jej wytwarzania i zastosowanie
MY137964A (en) Benzofuran derivative
NO20070972L (no) Benzyloksyderivater som MAOB-inhibitorer
MY139258A (en) Carbamoyl-type benzofuran derivatives
EA200301080A1 (ru) Терапевтический агент для лечения гиперфункции мочевого пузыря
DE602004009306D1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
EA200100723A1 (ru) Способ получения 1-(аминометил)циклогексилуксусной кислоты

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU